Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung Cancer

Lung Cancer

30 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Cancer

343 trials tracked for Lung Cancer: 37 in phase 3 or 4 and 13 with published results. The most-cited published study has 1665 citations.

343Trials tracked
37Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 4 Phase 3 33 Phase 2 177 Phase 1 14 Other / NA 115
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,665 cited
  2. Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 980 cited
  3. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 581 cited
  4. Phase 3 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC Completed · 398 cited
  5. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 268 cited
  6. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 220 cited
Show 44 more trials
  1. Phase 3 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Completed · 115 cited
  2. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  3. Phase 3 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed · 107 cited
  4. Phase 3 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 76 cited
  5. Phase 4 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed · 75 cited
  6. Phase 3 PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers Completed · 16 cited
  7. Phase 3 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed · 11 cited
  8. Phase 4 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed
  9. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  10. Phase 3 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Completed
  11. Phase 3 Iressa Follow-up Trial Completed
  12. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  13. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  14. Phase 3 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting Completed
  15. Phase 3 T790M Plasma Testing Methodology Comparison and Clinical Validation Completed
  16. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  17. Phase 3 A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Completed
  18. Phase 3 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Completed
  19. Phase 3 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Completed
  20. Phase 3 Bintrafusp Alfa Program Rollover Study Completed
  21. Phase 3 Evaluation of the Bio-Seal Biopsy Track Plug Completed
  22. Phase 3 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Completed
  23. Phase 3 National Lung Screening Trial (NLST) Screening Completed
  24. Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Completed
  25. Phase 3 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Completed
  26. Phase 3 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed
  27. Phase 3 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed
  28. Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
  29. Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
  30. Phase 3 Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
  31. Phase 3 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed
  32. Phase 2 Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Completed
  33. Phase 2 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed
  34. Phase 2 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions Completed
  35. Phase 2 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed
  36. Phase 2 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
  37. Phase 2 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Completed
  38. Phase 2 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  39. Phase 2 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  40. Phase 2 Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC Completed
  41. Phase 2 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Completed
  42. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  43. Phase 2 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy Completed
  44. Phase 2 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed

Showing the 50 most-cited and recently-updated of 343 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lung Cancer: what the trials found

New evidence indicates that Brigatinib significantly improves progression-free survival (PFS) and objective response rates (ORR) compared to standard treatments, with a notably higher intracranial ORR 20. Additionally, Cetuximab has been shown to improve overall survival in patients with lung cancer 21.

Radiation therapy is associated with significant differences in neurocognitive progression at 3 months, as well as variations in local and distant tumor control and quality of life scores 19. Regarding pharmacotherapy for smoking cessation, bupropion hydrochloride demonstrated a correlation between CYP2B6 alleles and metabolism status, though it did not show a statistically significant difference in salivary cotinine-verified abstinence at 6 months 15. Nicotine lozenges showed a statistically significant difference in 24-hour point prevalence abstinence at 6-month follow-up compared to a control group 18.

The combination of Nivolumab and Ipilimumab was evaluated for safety, reporting specific counts of high-grade drug-related adverse events and immune-mediated adverse events across different study arms 16. In trials involving nab-paclitaxel, there were no statistically significant differences in the percentage of patients experiencing peripheral neuropathy or myelosuppression, though dose reductions occurred frequently across groups 17.

Recent results — preliminary, needs further review

  • • VGT-309 showed a statistically significant reduction in Clinically Significant Events (p=<.0001) 2.
  • • KanSurive ECHO and Practice Facilitation were associated with statistically significant completion rates for tumor surveillance, distress screening, and BMI assessment 13.
  • • Clinical trials are investigating various supportive interventions including a Virtual Navigation System 3, CBCT Imaging [4, 14], one-fraction stereotactic body radiotherapy 5, the BioSpy System 6, MyLungHealth 7, transportation services 8, social determinants of health screening 9, light physical activity 10, systemic oncological treatment 11, and patient education 12.

For the clinician treating this condition

  • Brigatinib is associated with superior progression-free survival and intracranial objective response rates compared to other treatments 20.
  • Cetuximab has been established as an intervention that improves overall survival in lung cancer patients 21.
  • Radiation therapy impacts neurocognitive status and tumor control, while nicotine lozenges show statistically significant differences in abstinence at 6 months [18, 19].

AI synthesis of 18 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rapid on-site evaluation achieves 88.1% sensitivity and 91.7% specificity for lung cancer detection
Pulmonology & Critical Care Meta-analysis
Rapid on-site evaluation achieves 88.1% sensitivity and 91.7% specificity for lung cancer detection Rapid on-site testing improves lung cancer detection during bronchoscopy
This meta-analysis of diagnostic data evaluates the accuracy of rapid on-site evaluation (ROSE) during endobronchial ultrasound-guided bronc…
A new method of checking samples immediately during a procedure helps doctors more accurately identify lung cancer in specific cases.
Jul 26, 2026
DEB-BACE Shows Higher Short-Term Response in Unresectable Lung Cancer
Oncology Meta-analysis
DEB-BACE Shows Higher Short-Term Response in Unresectable Lung Cancer Drug Eluting Beads May Improve Treatment Success for Certain Lung Cancer Patients
A meta-analysis of 221 patients found that drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) improves short-term tumor resp…
A new review shows that using drug-eluting beads during a specific procedure may help shrink tumors more effectively than standard methods.
Frontiers Jul 22, 2026
Polygenic risk scores and air pollutants associated with increased lung cancer risk
Pulmonology & Critical Care RCT
Polygenic risk scores and air pollutants associated with increased lung cancer risk Genetic Scores and Air Pollution Linked to Lung Cancer Risk
This randomized controlled trial analyzed a cohort of 7,364 individuals to evaluate the impact of polygenic risk scores (PRS) and ambient ai…
New research shows that genetic risk scores and exposure to air pollutants are linked to higher lung cancer risk in a large screening group.
medRxiv Jul 20, 2026
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026
Individualised PEEP lowers driving pressure but not pulmonary complications in older lung cancer surgery patients
Pulmonology & Critical Care RCT
Individualised PEEP lowers driving pressure but not pulmonary complications in older lung cancer surgery patients Trial Shows Tailored Pressure Improves Oxygen During Lung Cancer Surgery
This RCT in 400 older adults undergoing lung cancer surgery found that individualised PEEP (EIT-guided) reduced driving pressure and improve…
Tailored breathing pressure improved oxygen levels during lung cancer surgery for older patients, though it did not change overall complicat…
Jul 4, 2026
Deep learning AI models for lung nodule malignancy classification show 88% sensitivity and 75% specificity
Pulmonology & Critical Care Meta-analysis
Deep learning AI models for lung nodule malignancy classification show 88% sensitivity and 75% specificity Artificial intelligence helps identify lung cancer in chest CT scans
This meta-analysis of 21 studies evaluated deep learning AI models for classifying lung nodules on chest CT. The analysis found high sensiti…
New data shows that deep learning models can help doctors identify lung cancer risks, though they still have some limits in accuracy.
Jul 4, 2026
WHO reporting system provides balanced diagnostic accuracy for malignancy risk in lung lesions
Pulmonology & Critical Care Meta-analysis
WHO reporting system provides balanced diagnostic accuracy for malignancy risk in lung lesions WHO reporting system helps doctors identify lung cancer risks
This meta-analysis evaluates the WHO reporting system for lung cytopathology in patients with lung lesions undergoing fine-needle aspiration…
A standardized reporting system helps doctors better identify the risk of lung cancer when analyzing tissue samples from patients with lung …
Jul 4, 2026
Non-pharmacological interventions may improve sleep quality, quality of life, and anxiety in lung cancer patients
Oncology Meta-analysis
Non-pharmacological interventions may improve sleep quality, quality of life, and anxiety in lung cancer patients Non-drug treatments may improve sleep and anxiety in lung cancer
This systematic review and meta-analysis of 2604 lung cancer patients found that non-pharmacological interventions may have a positive effec…
New data suggests that non-drug therapies can help lung cancer patients sleep better, feel less anxious, and improve their overall quality o…
Jun 29, 2026
Lung cancer screening identifies new solid nodules with a 7.4% malignancy rate at 12 months
Oncology RCT
Lung cancer screening identifies new solid nodules with a 7.4% malignancy rate at 12 months New lung cancer screening data identifies risk for solid nodules
This multicenter randomized controlled trial evaluated lung cancer screening in 875 high-risk individuals aged 50-75 years. The study found …
A study of 875 high-risk individuals shows that the size and growth speed of new lung nodules can help predict cancer risk.
Jun 20, 2026
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Radiology & Imaging Meta-analysis
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Jun 13, 2026
Lower baseline quality of life linked to 7% higher mortality risk in lung cancer patients
Oncology Meta-analysis
Lower baseline quality of life linked to 7% higher mortality risk in lung cancer patients Low quality of life before treatment links to higher death risk in lung cancer patients
This systematic review and meta-analysis of 20,235 lung cancer patients across 18 countries found that lower pre-treatment global quality of…
A large study of 20,235 lung cancer patients found that lower quality of life before treatment was linked to higher mortality risk.
Jun 5, 2026
Wearable monitoring reduced prolonged hospital stay from 24% to 7% in lung cancer surgery cohorts
Drug Pipeline Meta-analysis
Wearable monitoring reduced prolonged hospital stay from 24% to 7% in lung cancer surgery cohorts Wearable monitors and rehab support may help lung cancer patients recover faster after surgery
This narrative synthesis reviews eight reports representing seven independent cohorts of adults undergoing lung cancer surgery or clinically…
A review of eight studies found that using wearables or rehab support reduced long hospital stays. These tools showed promise for helping ad…
Frontiers Jun 4, 2026

Questions about Lung Cancer

How well does osimertinib work for lung cancer patients who have active brain metastasis?

Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.

Full answer →
Which method is best for placing fiducial markers before radiation for lung cancer?

Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.

Full answer →
Can a high neutrophil-to-lymphocyte ratio predict if lung cancer will spread to the brain?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.

Full answer →
What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.

Full answer →

All Lung Cancer Articles